Kestra Medical Technologies (NASDAQ:KMTS) Insider Traci Umberger Sells 7,590 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 7,590 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $23.86, for a total transaction of $181,097.40. Following the transaction, the insider owned 199,405 shares in the company, valued at approximately $4,757,803.30. The trade was a 3.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Performance

NASDAQ KMTS opened at $23.99 on Tuesday. The firm has a market capitalization of $1.41 billion, a P/E ratio of -9.91 and a beta of 0.58. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The firm’s fifty day moving average price is $22.62 and its two-hundred day moving average price is $22.48. Kestra Medical Technologies, Ltd. has a 1 year low of $14.10 and a 1 year high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The firm had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. As a group, research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. BTIG Research upped their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Oppenheimer assumed coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating for the company. Finally, Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.83.

Institutional Trading of Kestra Medical Technologies

Several hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new stake in Kestra Medical Technologies during the 1st quarter worth approximately $11,036,000. Woodline Partners LP acquired a new position in Kestra Medical Technologies in the 1st quarter valued at $2,510,000. Jane Street Group LLC bought a new position in Kestra Medical Technologies during the 1st quarter worth $756,000. Geode Capital Management LLC increased its position in Kestra Medical Technologies by 718.5% during the 2nd quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock worth $5,395,000 after buying an additional 285,579 shares during the period. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Kestra Medical Technologies during the second quarter worth $256,000.

Trending Headlines about Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Neutral Sentiment: Multiple executives, including CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran, sold shares between July 30 and August 3. The transactions totaled approximately 103,000 shares and more than $2.3 million at prices near $22.60–$23.92. Each filing states that the sales were made to cover tax-withholding obligations tied to vested equity awards, rather than for discretionary investment purposes. SEC insider transaction filings
• Negative Sentiment: The breadth of the selling—including transactions by the CFO and several other insiders—could weigh on sentiment because it reduces management ownership and creates a perception of insider selling pressure. However, the relatively small percentage reductions in most positions and the disclosed tax-related purpose make the signal less bearish than open-market sales based on an expectation of weaker business performance.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.